Forest Laboratories will acquire Clinical Data to add to its portfolio of drugs to treat depression, The Wall Street Journal reports. The company will pay about $30 a share in cash, totaling about $1.2 billion.
It will also pay an additional $6 a share based on the sales of performance of its approved antidepressant, Viibryd. The deal is expected to be completed by the second quarter of 2011.
Click here for the story from The Wall Street Journal.
Click here for the additional coverage from Reuters.